This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Outcomes assessed in the review
The main health outcomes considered were: operative death, transfusion reaction (fatal, non-fatal), transfusion infections (hepatitis C, B, HIV, Human T cell lymphotropic virus (HTLV) types I/II), transfusion infection outcome (fulminant hepatitis, hospitalisation acute hepatitis, symptom acute hepatitis, hepatitis C resolve, symptomatic chronic hepatitis C, hepatitis B resolve, symptomatic chronic hepatitis B, chronic active hepatitis B or C, interferon for chronic active hepatitis B or C, liver biopsy if interferon, HTLV I/II myelopathy), quality of life adjustments, and life expectancy.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Ten studies were included in the review.
Methods of combining primary studies
Narrative.
Investigation of differences between primary studies
Not performed.
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Results of the review
The values assigned to decision analysis variables were as follows: Life expectancy values were as follows: 12.3 for AAA reconstruction, 17.63 for AIOD reconstruction; excess mortality, none for AAA and 0.059 for AIOD reconstruction, 0.0035 for chronic hepatitis; 9 for HIV/AIDS.
Measure of benefits used in the economic analysis
QALYs and life expectancy were used as the measures of benefits in the economic analysis.
Direct costs
Direct health service costs were considered: the costs of the CS, allogenic packed red blood cells (PRBC), and transfusion related complications. The cost of CS included the cost of equipment, all disposable items, maintenance and dedicated personnel.1996 prices were used. Costs were reported separately. All costs that were accrued in the future were discounted at 5%. Quantities were not reported separately.
Statistical analysis of costs
Indirect Costs
Not considered.
Currency

US dollars ($).
Sensitivity analysis
Extensive sensitivity analyses were performed on the model variables.
Estimated benefits used in the economic analysis
Routine use of CS during elective infrarenal aortic reconstructions added only 0.00218 QALYs for AAA reconstructions and 0.00062 QALYs for AIOD reconstructions.
